Icon

NEXLIZET (nda211617)- (180MG;10MG)

BEMPEDOIC ACID; EZETIMIBE ESPERION THERAPS INC
180MG;10MG
Yes Yes
2040-Jun-19 2025-Feb-21
None 2023-Feb-26
None No
NEXLIZET, which contains an adenosine triphosphate-citrate lyase (ACL) inhibitor and a cholesterol absorption inhibitor, is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
0 0 0
Total Other Developers 19
Drugs with Suitability No
180MG;10MG ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.